RE:RE:AstraZeneca's ADC disappoints - on severe adverse eventsNovember16, 2023 - [Regeneron's] Lowy says there’s a lot of room for improvement in ADCs. While he acknowledges there have been breakthroughs in prolonged, durable responses and improved survival, the therapies can be tough on patients. “At the end of the day, though, it is still a chemotherapy. Granted, the idea is to deliver this chemotherapy in a much more targeted fashion so that there's less systemic toxicity,” Lowy said. “It's hard to make them completely kind and gentle. At the same time, immunotherapy is not without its side effects also, so there's no free lunch.”
The promise in ADCs lies with combinations, which have become the standard in oncology care. Lowy believes that just as chemotherapy can combine with immunotherapy, ADCs will be able to as well.
https://www.fiercebiotech.com/biotech/regeneron-stays-out-adc-deal-fray-house-scientists-tinker